375 related articles for article (PubMed ID: 21666706)
1. Anti-γδ TCR antibody-expanded γδ T cells: a better choice for the adoptive immunotherapy of lymphoid malignancies.
Zhou J; Kang N; Cui L; Ba D; He W
Cell Mol Immunol; 2012 Jan; 9(1):34-44. PubMed ID: 21666706
[TBL] [Abstract][Full Text] [Related]
2. Adoptive immunotherapy of lung cancer with immobilized anti-TCRgammadelta antibody-expanded human gammadelta T-cells in peripheral blood.
Kang N; Zhou J; Zhang T; Wang L; Lu F; Cui Y; Cui L; He W
Cancer Biol Ther; 2009 Aug; 8(16):1540-9. PubMed ID: 19471115
[TBL] [Abstract][Full Text] [Related]
3. Anti-lymphoma effect of gammadelta T cells.
Kunzmann V; Wilhelm M
Leuk Lymphoma; 2005 May; 46(5):671-80. PubMed ID: 16019504
[TBL] [Abstract][Full Text] [Related]
4. Bispecific T-cells expressing polyclonal repertoire of endogenous γδ T-cell receptors and introduced CD19-specific chimeric antigen receptor.
Deniger DC; Switzer K; Mi T; Maiti S; Hurton L; Singh H; Huls H; Olivares S; Lee DA; Champlin RE; Cooper LJ
Mol Ther; 2013 Mar; 21(3):638-47. PubMed ID: 23295945
[TBL] [Abstract][Full Text] [Related]
5. Activating and propagating polyclonal gamma delta T cells with broad specificity for malignancies.
Deniger DC; Maiti SN; Mi T; Switzer KC; Ramachandran V; Hurton LV; Ang S; Olivares S; Rabinovich BA; Huls MH; Lee DA; Bast RC; Champlin RE; Cooper LJ
Clin Cancer Res; 2014 Nov; 20(22):5708-19. PubMed ID: 24833662
[TBL] [Abstract][Full Text] [Related]
6. Systemic β-Adrenergic Receptor Activation Augments the
Baker FL; Bigley AB; Agha NH; Pedlar CR; O'Connor DP; Bond RA; Bollard CM; Katsanis E; Simpson RJ
Front Immunol; 2019; 10():3082. PubMed ID: 32038628
[TBL] [Abstract][Full Text] [Related]
7. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
[TBL] [Abstract][Full Text] [Related]
8. Preferential expansion of Vgamma9-JgammaP/Vdelta2-Jdelta3 gammadelta T cells in nasal T-cell lymphoma and chronic active Epstein-Barr virus infection.
Oyoshi MK; Nagata H; Kimura N; Zhang Y; Demachi A; Hara T; Kanegane H; Matsuo Y; Yamaguchi T; Morio T; Hirano A; Shimizu N; Yamamoto K
Am J Pathol; 2003 May; 162(5):1629-38. PubMed ID: 12707047
[TBL] [Abstract][Full Text] [Related]
9. Co-Expansion of Cytokine-Induced Killer Cells and Vγ9Vδ2 T Cells for CAR T-Cell Therapy.
Du SH; Li Z; Chen C; Tan WK; Chi Z; Kwang TW; Xu XH; Wang S
PLoS One; 2016; 11(9):e0161820. PubMed ID: 27598655
[TBL] [Abstract][Full Text] [Related]
10. CCL17 and CCL22/CCR4 signaling is a strong candidate for novel targeted therapy against nasal natural killer/T-cell lymphoma.
Kumai T; Nagato T; Kobayashi H; Komabayashi Y; Ueda S; Kishibe K; Ohkuri T; Takahara M; Celis E; Harabuchi Y
Cancer Immunol Immunother; 2015 Jun; 64(6):697-705. PubMed ID: 25754123
[TBL] [Abstract][Full Text] [Related]
11. Universal Ready-to-Use Immunotherapeutic Approach for the Treatment of Cancer: Expanded and Activated Polyclonal γδ Memory T Cells.
Polito VA; Cristantielli R; Weber G; Del Bufalo F; Belardinilli T; Arnone CM; Petretto A; Antonucci L; Giorda E; Tumino N; Pitisci A; De Angelis B; Quintarelli C; Locatelli F; Caruana I
Front Immunol; 2019; 10():2717. PubMed ID: 31824502
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of expanded human tumor-infiltrating gammadelta T lymphocytes.
Chen J; Niu H; He W; Ba D
Int Arch Allergy Immunol; 2001 Jul; 125(3):256-63. PubMed ID: 11490159
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity and some immunological properties of gammadelta T-cells from patients with gastrointestinal carcinomas.
Murayama M; Tanaka Y; Yagi J; Uchiyama T; Ogawa K
Anticancer Res; 2008; 28(5B):2921-31. PubMed ID: 19031935
[TBL] [Abstract][Full Text] [Related]
14. Highly active microbial phosphoantigen induces rapid yet sustained MEK/Erk- and PI-3K/Akt-mediated signal transduction in anti-tumor human gammadelta T-cells.
Correia DV; d'Orey F; Cardoso BA; Lança T; Grosso AR; deBarros A; Martins LR; Barata JT; Silva-Santos B
PLoS One; 2009 May; 4(5):e5657. PubMed ID: 19479075
[TBL] [Abstract][Full Text] [Related]
15. Development of Innate-Immune-Cell-Based Immunotherapy for Adult T-Cell Leukemia-Lymphoma.
Nakashima M; Tanaka Y; Okamura H; Kato T; Imaizumi Y; Nagai K; Miyazaki Y; Murota H
Cells; 2024 Jan; 13(2):. PubMed ID: 38247820
[TBL] [Abstract][Full Text] [Related]
16. Anti-tumor cytotoxicity of gammadelta T cells expanded from peripheral blood cells of patients with myeloma and lymphoma.
Saitoh A; Narita M; Watanabe N; Tochiki N; Satoh N; Takizawa J; Furukawa T; Toba K; Aizawa Y; Shinada S; Takahashi M
Med Oncol; 2008; 25(2):137-47. PubMed ID: 18488155
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of gammadelta T cells reactive against cytomegalovirus-infected cells in a mouse xenograft tumor model.
Devaud C; Bilhere E; Loizon S; Pitard V; Behr C; Moreau JF; Dechanet-Merville J; Capone M
Cancer Res; 2009 May; 69(9):3971-8. PubMed ID: 19383918
[TBL] [Abstract][Full Text] [Related]
18. Intravesical administration of gammadelta T cells successfully prevents the growth of bladder cancer in the murine model.
Yuasa T; Sato K; Ashihara E; Takeuchi M; Maita S; Tsuchiya N; Habuchi T; Maekawa T; Kimura S
Cancer Immunol Immunother; 2009 Apr; 58(4):493-502. PubMed ID: 18682944
[TBL] [Abstract][Full Text] [Related]
19. Type I IFN-mediated enhancement of anti-leukemic cytotoxicity of gammadelta T cells expanded from peripheral blood cells by stimulation with zoledronate.
Watanabe N; Narita M; Yokoyama A; Sekiguchi A; Saito A; Tochiki N; Furukawa T; Toba K; Aizawa Y; Takahashi M
Cytotherapy; 2006; 8(2):118-29. PubMed ID: 16698685
[TBL] [Abstract][Full Text] [Related]
20. Gamma delta T cells from HIV+ donors can be expanded in vitro by zoledronate/interleukin-2 to become cytotoxic effectors for antibody-dependent cellular cytotoxicity.
Poonia B; Pauza CD
Cytotherapy; 2012 Feb; 14(2):173-81. PubMed ID: 22029653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]